In addition to tumour size, receptor status, inflammatory features, proliferative rate, and grade, HER2/neu overexpression and expression of p53 protein have recently been identified as prognostic indicators in the treatment of standard risk breast (Muss et al, 1994; Paik et al, 1998; Thor et al, 1998; Paik et al, 2000). Here, ERBB2 is linked to neoplasm.